Comunicati Stampa
Scienza e Tecnologia

Brains Bioceutical receives official confirmation of Valid Novel Foods Application from the UK FSA Commission

The value of the UK CBD market is reported to be greater than that of vitamin C and D combined [1]. CBD is seeing monumental demand in Europe and the market is on course to grow 400 per cent over the next four years. According to New Frontier Data EU CBD Consumer Report: 46 per cent  of Europeans view CBD favourably, and up to 77 per cent of surveyed respondents also believe CBD should be accessible in some way. [2] The value of the UK CBD market is reported to be greater than that of vitamin C...
VANCOUVER, BC, (informazione.news - comunicati stampa - scienza e tecnologia)

The value of the UK CBD market is reported to be greater than that of vitamin C and D combined . CBD is seeing monumental demand in Europe and the market is on course to grow 400 per cent over the next four years. According to New Frontier Data EU CBD Consumer Report: 46 per cent  of Europeans view CBD favourably, and up to 77 per cent of surveyed respondents also believe CBD should be accessible in some way.

Advancements made by Brains Bio in the development of pure, natural CBD benefit the scientific and healthcare community globally. Brains Bio's CBD API has successfully been tested by the INRS Laboratory, a World Anti-Doping Agency (WADA) facility. These screening reports have confirmed that the CBD API is free of THC, pesticides, and other banned substances listed by WADA. Brains Bio is the first of its kind in the industry to get such confirmation from a WADA-accredited laboratory for the purity of its CBD and the absence of prohibitory substances. WADA has removed CBD from its banned substance list. All activities undertaken in the UK are in accordance with UK law and subject to routine, periodic inspection by UK authorities.  


Brains Bio is the leader in evidence-based cannabinoid and phytochemical active pharmaceutical ingredients (API) to enhance life and treatment options for consumers and patients. Based in the United Kingdom , Brains Bio is one of the only producers of natural hemp-based cannabinoid APIs in the world. Combined with the company's unparalleled expertise and institutional knowledge in biotechnology, pharmaceuticals and cannabinoid-based product development, Brains Bio is strategically positioned to be a trailblazer in healthcare innovation across the world. 

For further information: Rachael Marshall , 289 925 8041, rachaelm@durrellcomm.com

Logo - https://mma.prnewswire.com/media/1734987/Brains%C2%A0Bioceutical%C2%A0Corp__Brains_Bioceutical%C2%A0receives_official_co.jpg

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili